-transparent.png){kind=logo}
The weak antiallergic activity of 6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid (4) on the rat reaginic passive cutaneous anaphylaxis test was enhanced by the introduction of appropriate functional groups into position 9 of the pyridopyrimidine ring. The most active 9-substituted pyridopyrimidinecarboxylic acids contained an oxime, a phenylamino, or a (phenylamino)thioxomethyl group in position 9. The 9-phenylcarboxamido and 9-phenylhydrazono moieties may be regarded as bioisosteric groups in the pyridopyrimidinone series. In the series of 9-(arylamino)dihydropyridopyrimidines, the structure-activity relationship study revealed similar relationships as found for the 9-(arylhydrazono)tetrahydropyridopyrimidines. The biological activity was due to the 6S enantiomers. A monosubstituted arylamino moiety in position 9 was necessary for the intravenous activity. The most active compound, 9-[(3-acetylphenyl)amino]-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H- pyrido[1,2-a]pyrimidine-3-carboxylic acid (40) was three times as active as the reference sodium chromoglycate (DSCG) in the passive cutaneous anaphylaxis (PCA) test.
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
October 1984,
Journal of medicinal chemistry,
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
January 1992,
Acta physiologica Hungarica,
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
March 2021,
RSC advances,
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
January 1995,
Farmaco (Societa chimica italiana : 1989),
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
November 2016,
Scientific reports,
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
September 1993,
Farmaco (Societa chimica italiana : 1989),
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
July 2009,
Acta crystallographica. Section E, Structure reports online,
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
October 2011,
Organic & biomolecular chemistry,
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
November 2012,
Bioorganic & medicinal chemistry,
I Hermecz, and
T Breining, and
L Vasvári-Debreczy, and
A Horváth, and
Z Mészáros, and
I Bitter, and
C DeVos, and
L Rodriguez
February 2023,
Molecules (Basel, Switzerland),
